Interleukin 21 (IL-21) medicine for cancer therapy
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- 乘典(苏州)生物医药有限公司
- Publication Date
- 2012-11-14
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The present invention relates to the field of tumor treatment. In particular, the invention relates to the use of interleukin-21 in the treatment of tumors. More specifically, the present invention relates to the treatment of breast cancer using a fusion protein of interleukin 21 and an anti-Her2 / neu single chain antibody. Background technique
[0002] The body's immunity plays an important role in the occurrence and development of tumors. In recent years, studies have found that the body's anti-tumor immune response also plays an important role in the therapeutic effects of conventional tumor radiotherapy and chemotherapy. Tumor radiotherapy and chemotherapy lead to massive death of tumor cells, release tumor antigens and a series of "danger signals", activate the body's innate immune signaling pathway, promote the uptake, processing and presentation of antigens by antigen-presenting cells, and induce and enhance the body's anti-tumor immune response...